Encouraging initial results to date in field validation trialsToolbox Medical Innovations engaged for the design of the commercial test kitNDA Group engaged to assist in progress towards CE markingAdditional international advisory board members: Paul Field (Australia) and Charles Pan … [Read more...]

Zurich, 30 October 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) announces that following the financing round communicated on the 29th July 2020, its share capital recorded in the commercial register has been increased by 13,165,476 shares to 102,797,618 shares. The new shares have been issued out … [Read more...]

New international advisory board members: Mr Glenn Cross (Australia), Dr Jittaporn Wattanaseree (Thailand) and Ms Carol Aebi (Switzerland)Management team appointment: Mr Pierre Nathie of Med2Mark as VP, CommercialisationZurich, 13 October 2020--Achiko AG (SWX:ACHI, ISIN CH0522213468) is pleased … [Read more...]

The outbreak of the Covid-19 pandemic towards the end of first quarter 2020 limited Achiko’s ability to execute on its business strategyAchiko responded by developing a Covid-19 testing and ecosystem platform Teman Sehat, and by securing a complementary testing technology codenamed “Gumnuts” to … [Read more...]

Zurich, 28 August 2020 –Achiko AG (SWX:ACHI, ISIN CH0522213468) is selling its stake in the company EmpatKali. The buyer of EmpatKali is Afterpay, a public listed company. EmpatKali offers a “buy now, pay later” business.Achiko will receive the initial investment of USD 100,000. The proceeds of … [Read more...]